Geniposide is an iridoid glycosides purified from the fruit of Gardenia jasminoides Ellis, which is known to have antiinflammatory, antioxidative and anti-tumor activities. The present study aimed to investigate the effects of geniposide on experimental rat colitis and to reveal the related mechanisms. Experimental rat colitis was induced by rectal administration of a TNBS solution. The rats were treated with geniposide (25, 50 mg·kg
Introduction
Intestinal inflammation is related to multiple factors including inflammatory bowel disease (IBD) . Although the precise etiology of IBD remains unknown [1] , it is mainly caused by ulcerative colitis and Crohn's disease [2] . Crohn's disease causes inflammation that extends through the entire bowel wall, whereas ulcerative colitis affects the colon and/or the large intestine [3] . Geniposide (Figure 1 ), an iridoid glycosides purified from the fruit of Gardenia jasminoides Ellis, is known to have antiinflammatory, anti-oxidative and anti-tumor effects [4] [5] [6] . The anti-inflammatory effects of geniposide have been found to ameliorate arthritis and mastitis [7, 8] . However, whether geniposide can effectively ameliorate intestinal inflammation www.chinaphar.com Xu B et al Acta Pharmacologica Sinica remains unknown. The present study was designed to investigate the effects of geniposide on intestinal inflammation.
To provide valuable information for the potential clinical treatment of bowel inflammation, in the present study, both 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced experimental ulcerative colitis in rats and lipopolysaccharide (LPS)-infected Caco-2 cell monolayers were used as experimental intestinal inflammatory models, and sulfasalazine (SASP) was used as a positive control drug to evaluate and characterize geniposide-induced modulation and reveal the related mechanisms.
Materials and methods

Animals
Male Sprague-Dawley (SD) rats weighing 180-220 g were obtained from the Experimental Animal Center of Dalian Medical University (Certificate of Conformity: No SCXK 2008-0002). The experimental protocol was carried out based on the Declaration of Helsinki and supported by Dalian Medical University Animal Care and Ethics Committee. All rats were housed at a temperature of 22±2 °C, maintained on a 12:12-h light-dark cycle, and provided with food and water ad libitum. Rats were acclimatized for 1 week before the initiation of the study.
Establishment of experimental rat colitis
The rat model of colitis was induced by rectal administration of TNBS according to previously described methods [9] . After a 24-h period of fasting with ad libitum access to water, a TNBSethanol solution (50% v/v) was administered through a catheter into the rat colon at a dose of 100 mg/kg under urethane anesthesia (1.25 g/kg, ip). The vehicle control group was treated with 50% ethanol alone.
Rats were randomly divided into six experimental groups with ten rats in each group: (1) vehicle control group, (2) vehicle + geniposide (H, 50 mg/kg) group, (3) TNBS-treated group, (4) TNBS+SASP (100 mg/kg) group, (5) TNBS+geniposide (L, 25 mg/kg) group, and (6) TNBS+geniposide (H, 50 mg/kg) group. The vehicle and TNBS group were given an equal volume of saline. Agents used in the assay were prepared using saline. Starting 24 h after the initiation of TNBS-induced inflammation, saline, sulfasalazine (100 mg/kg), or geniposide (25, 50 mg/kg) was intragastrically administered once daily in all 6 groups for 14 consecutive days.
Rat food intake, body weight, stool consistency (degree of diarrhea), and blood in stool were recorded daily. Rats were sacrificed on d 15, the colon was removed, and the length and weight were measured. The isolated colon was fixed in 4% paraformaldehyde for 24 h and embedded in paraffin. Colon samples were prepared and stained with hematoxylin and eosin (H&E) and then assessed under light microscopy. The pathologic score of the colonic damage was evaluated according to previously described morphological criteria [10, 11] . Rats were denied access to food but allowed water for 3 h. Then, 150 μL fluorescein isothiocyanate-4 kDa dextran (80 mg/mL, Sigma) was gavaged, and serum was harvested 1 and 3 h later. Serum recovery was measured using a Synergy HT plate reader (BioTek, Winooski, VT, USA) as previously reported [12] .
LPS-infected Caco-2 cells
Caco-2 cells obtained from the ATCC (Rockville, MD, USA) and cultured in Dulbecco's modified Eagle's medium (DMEM, Gibco) containing 10% fetal bovine serum (FBS, Gibco) were given 1% non-essential amino acids and 1% glutamine. All of the media contained 50 U/mL penicillin and 50 U/mL streptomycin. All cells were maintained at 37 °C in a humidified atmosphere of air and 5% CO 2 . LPS (1 μg/mL)-stimulated Caco-2 cells were treated with geniposide or an equal volume of vehicle. Transepithelial electrical resistance (TER) was measured to evaluate the epithelial barrier function in vitro. Decreased TER is a significant indicator of barrier dysfunction [13] . An epithelial voltohmmeter was used for the measurement of TER of filter-grown Caco-2 intestinal monolayers as previously reported [14] . TER of Caco-2-plated filters was measured daily. A steady state of TER was achieved after 21 d (always 540±12 Ω·cm 2 ), indicating that the barrier function model was established, and Caco-2-plated filters could be used.
Cell transfection
Caco-2 cells were transfected with small interfering RNA (siRNA) or c-DNA as previously described [15] . Caco-2 cells were placed into 6-well plates for 24 h. Cells were transfected with specific siRNA (Genepharma, Shanghai, China) or c-DNA targeting AMPK with Lipofectamine 2000 (Invitrogen). After transfection for 48 h, the cells were infected with LPS or LPS+geniposide (50 μg/mL) for an additional 24 h. Then, cells were collected for Western blot analysis.
ELISA assays
The expression levels of pro-inflammatory cytokines and mediators, including tumor necrosis factor-alpha (TNF-α), interleukin-1-beta (IL-1-β), interleukin-6 (IL-6), and myeloperoxidase (MPO), in the rat colon were determined using double-antibody sandwich ELISAs (R&D Systems, USA) according to the manufacturer's instructions.
Western blot analysis
Equal amounts of protein were subjected to Western blot analysis as previously described [16] . Protein lysates from both rats and cells were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes. Membranes were blotted for specific antibodies, including MLCK (Abcam, Cambridge, UK), occludin, ZO-1 (Santa Cruz Biotechnology), NF-κB p65, p-p65, iNOS, COX-2, p-AMPK, and AMPK (CST, Beverly, MA, USA). The blots were developed using an enhanced chemiluminescence method (GE Healthcare). Quantification was performed by densitometric analysis of specific bands on the immunoblots using a Multi Spectral imaging system (UVP, Cambridge, UK). Reagents Geniposide (purity >98%) was purchased from Chengdu Must Bio-Technology Co (Chengdu, China). Unless otherwise indicated, all chemicals were obtained from Sigma-Aldrich (St Louis, MO, USA).
Statistical analysis
All data are shown as the mean±standard deviation (SD).
One-way analysis of variance (ANOVA) was used where three or more groups of data were compared. All experiments were repeated at least three times, and a P value of less than 0.05 (P<0.05) was considered statistically significant.
Results
Establishment of TNBS-induced experimental colitis in rats
Body weight and food intake of TNBS-treated rats ( Figure  2A , 2B) were significantly reduced compared with those of the vehicle control group. Macroscopically visible damage, as measured by the disease activity index (DAI) and the colon weight-to-length ratio ( Figure 2C , 2D), was significantly higher in the rats with TNBS-induced experimental colitis than in the vehicle control. Significant tissue injuries with high microscopic damage scores were found using histological examination ( Figure 2E , 2F) of resected colons from TNBS-treated rats. Both geniposide (25, 50 mg/kg) and the positive control SASP (100 mg/kg) significantly increased the TNBS-decreased body weight and ameliorated TNBS-induced experimental rat colitis and related symptoms. Although not significant, geniposide decreased the body weight of rats compared with that of the vehicle controls.
Geniposide-induced amelioration on intestinal inflammation in vivo
Inflammatory cytokine release and neutrophil infiltration play important roles in the process of inflammation [17] [18] [19] . The present study indicated that levels of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6) and myeloperoxidase (MPO) activity in the resected colon from TNBS-treated rats were significantly higher than in the vehicle control ( Figure 3A) . Geniposide (25, 50 mg/kg) significantly decreased both the increased proinflammatory cytokines and enhanced MPO activity.
NF-κB plays an important role in inflammatory processes, initiating transcription of pro-inflammatory cytokine genes [20] . Inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2) are also involved in the process of inflammation [21] . Our results indicated that the expression levels of NF-κB, COX-2, and iNOS proteins were significantly increased in TNBS-treated rats compared with those in the vehicle control rats ( Figure 3B ). Both geniposide (25, 50 mg/kg) and the positive control SASP (100 mg/kg) down-regulated the increased expression of NF-κB, COX-2, and iNOS proteins in TNBStreated rats.
Geniposide-induced amelioration of intestinal barrier dysfunction in vivo
Intestinal barrier dysfunction is found to cause increased intestinal permeability characterized by enhanced serum recovery of FD-4 [22, 23] . Decreased AMPK phosphorylation, increased MLCK protein expression, and decreased occludin/ ZO-1 protein expression (tight junction) are also found to be related to the destruction of intestinal barrier function [24] [25] [26] [27] . Our results showed that serum FD-4 was significantly higher in TNBS-treated rats than in vehicle control rats. Both geniposide (25, 50 mg/kg) and the positive control SASP (100 mg/kg) reversed the increased serum recovery of FD-4 in TNBS-treated rats ( Figure 4A ). AMPK phosphorylation was decreased in TNBS-treated rats. Geniposide (25, 50 mg/kg) treatment reversed the decrease in AMPK phosphorylation in TNBS-treated rats ( Figure 4B ). The protein expression of MLCK was significantly higher in TNBS-treated rats than in vehicle control rats. Geniposide (25, 50 mg/kg) treatment significantly down-regulated the increased protein expression of MLCK in TNBS-treated rats ( Figure 4C ). Tight junction protein expression (occludin and ZO-1) was decreased in TNBStreated rats. Geniposide (25, 50 mg/kg) treatment reversed the decrease in the protein expression of occludin and ZO-1 in TNBS-treated rats ( Figure 4D ).
Geniposide-induced amelioration of barrier dysfunction in vitro
The damage to Caco-2 cells induced by LPS leads to a reduction in TER [28] . As shown in Figure 5 , geniposide at final concentrations of 25 to 100 μg/mL significantly elevated the decreased TER ( Figure 5A ). With an incubation time of 12 to 48 h, geniposide at a concentration of 50 μg/mL significantly increased LPS-reduced TER ( Figure 5B) .
Destruction of barrier function is found in colitis [29] . Our results showed that the expression levels of occludin and ZO-1 protein were significantly lower ( Figure 5C , 5D) in LPSinfected Caco-2 cells than in the control Caco-2 cells. Geniposide (25, 50, 100 μg/mL) significantly elevated the reduced occludin and ZO-1 protein expression in LPS-infected Caco-2 cells.
Geniposide-induced amelioration of inflammation in vitro
The results showed that the expression levels of NF-κB, COX-2, and iNOS proteins were significantly higher in LPS-infected Caco-2 cells (Figure 6A-6C ) than in control Caco-2 cells. Geniposide (25, 50, 100 μg/mL) significantly down-regulated NF-κB, COX-2, and iNOS protein expression in LPS-infected Caco-2 cells.
Geniposide-induced modulation of the AMPK/MLCK pathway Decreased AMPK phosphorylation is found in LPS-infected Caco-2 cells [30] . At doses of 50-100 μg/mL ( Figure 7A ) and with incubation times of 12-48 h ( Figure 7B ), geniposide significantly enhanced the decreased AMPK phosphorylation in LPS-infected Caco-2 cells in a dose-and time-dependent manner. Both siRNA-inhibited and cDNA-facilitated endogenous expression of AMPK in Caco-2 cells were used to further characterize the role of geniposide in the modulation of AMPK. The results indicated that geniposide-mediated AMPK up-regulation was significantly abrogated following AMPK siRNA 
Discussion
Geniposide, a traditional Chinese medicine from the fruit of Gardenia jasminoides Ellis, has been found to possess antidiarrheal, hepatoprotective, anti-inflammatory, and anti-endotoxin activities [31] [32] [33] . Recent studies have shown that geniposide is an efficient anti-inflammatory agent in experimental arthritis and mastitis [7, 34] . The present study was carried out to reveal the characteristics of geniposide in the protection against and amelioration of experimental rat intestinal inflammation and the underlying mechanisms.
In the present study, geniposide (25, 50 mg/kg) ameliorated TNBS-induced experimental rat colitis and related symptoms. Geniposide significantly increased the TNBS-decreased body weight compared with that of the TNBS controls, demonstrating its ameliorative effects; however, geniposide was found to decrease the body weight of rats compared with that of vehicle controls without statistical significance (Figure 2 ). This phenomenon can be explained as follows. Geniposide is one of the active ingredients in traditional Chinese medicine used to fight obesity [35] . For instance, geniposide has been used for the amelioration of spontaneously obese type 2 diabetic mice and has been shown to suppress body weight and visceral fat accumulation [36] . Inflammatory cytokine release and neutrophil infiltration play an important role in colitis; MPO can indirectly reflect the vitality of neutrophil infiltration [37] . NF-κB, an important regulatory factor of inflammation, regulates the expression of genes that are involved in the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 [38] . A pro-inflammatory cytokine inhibitor such as infliximab, an anti-TNF-α antibody, is used in treatment of IBD patients [39] . iNOS and COX-2 are also involved in the process of inflammation, regulating the expression of inflammatory mediators NO and PGE2 [40, 41] . The above-mentioned evidence indicates that increased expression of inflammatory mediators is found in intestinal inflammation, suggesting that down-regulation of those inflammatory mediators would be beneficial in the amelioration of intestinal inflammation. The present study indicated that geniposide treatment not only improved the symptoms of TNBS-treated rats, including reversing the decreased body weight and food intake and the amelioration of histological injury, but also reduced MPO activity and down-regulated pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 and protein expression of NF-κB, iNOS and COX-2, indicating the potential mechanisms involved in geniposide-induced amelioration of TNBS-induced experimental colitis.
Damaged intestinal epithelial barrier function is correlated with triggering or worsening intestinal inflammatory disorder [42] . Both maintenance and disruption of epithelial barrier function are related to intestinal inflammation. For instance, intestinal barrier dysfunction is found to result in increased intestinal permeability characterized by enhanced serum recovery of FD-4 [22, 23] . AMPK activity has a specific role in epithelial barrier function [43] . LPS-induced endothelial hyperpermeability occurs in parallel with a decrease in AMPK activity. [30] . Increased MLCK protein expression and decreased occludin/ZO-1 protein expression (tight junction) are also found to induce the destruction of intestinal barrier function [25] [26] [27] . All of these studies indicate that the amelioration of the disruption of epithelial barrier function, characterized by restoration of these parameters back to normal, is therapeutically beneficial.
Our results indicated that the mechanisms involved in geniposide-ameliorated intestinal epithelial barrier dysfunction in TNBS-treated rats had the following characteristics. Geniposide reversed the increase in the serum recovery of FD-4, enhanced AMPK phosphorylation, inhibited the increase in protein expression of MLCK, and reversed the decrease in the protein expression of occludin and ZO-1. Consistent with the above results obtained from the in vivo experiments, geniposide also significantly reversed the decrease in TER in LPSinfected Caco-2 cells.
Geniposide-induced modulation of epithelial barrier dysfunction was confirmed by in vitro assays. Geniposide significantly up-regulated the decreased p-AMPK ( Figure 7A , 7B) and significantly down-regulated the increased MLCK protein expression ( Figure 8A , 8B) in LPS-infected Caco-2 cells. As AMPK activation has been found to inhibit MLCK [44, 45] , these results suggest that geniposide attenuates LPS-induced intestinal barrier dysfunction by AMPK up-regulation and activation (phosphorylation). It should be noted that following AMPK siRNA transfection, geniposide neither up-regulated AMPK protein expression ( Figure 7C ) nor down-regulated the increased MLCK protein expression ( Figure 8C) . Similarly, following cloning of MLCK cDNA, geniposide neither further up-regulated the increased AMPK protein expression ( Figure  7D ) nor further down-regulated the MLCK protein expression ( Figure 8D ) in LPS-infected Caco-2 cells, showing that geniposide-induced modulation is characterized by reversing the disrupted epithelial function back to normal.
The present study indicated that geniposide treatment ameliorated TNBS-induced experimental colitis in vivo and attenuated LPS-induced barrier dysfunction in vitro by reducing proinflammatory cytokine release and restoring impaired intestinal barrier function. Geniposide down-regulates the protein expression of MLCK by activating AMPK phosphorylation. Our results suggest that geniposide has potential clinical implications for alleviating intestinal inflammatory disorders. Effects of geniposide (0, 25, 50, 100 μg/mL) on the increased nuclear factor kappa-B (NF-κB) p65 phosphorylation (A), inducible nitric oxide synthase (iNOS) (B), and cyclooxygenase 2 (COX-2) protein expression (C) induced by LPS in the Caco-2 monolayer. All data are expressed as the mean±SD. n=3. 
